Koshinski Asset Management Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 8.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 161,192 shares of the biopharmaceutical company’s stock after acquiring an additional 11,904 shares during the quarter. Pfizer accounts for 1.5% of Koshinski Asset Management Inc.’s portfolio, making the stock its 2nd largest position. Koshinski Asset Management Inc.’s holdings in Pfizer were worth $5,838,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Janus Henderson Group PLC increased its position in Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. boosted its stake in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC bought a new position in Pfizer during the 2nd quarter valued at $268,389,000. Stifel Financial Corp boosted its stake in Pfizer by 5,413.5% during the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after purchasing an additional 7,226,697 shares in the last quarter. Finally, Longview Partners Guernsey LTD boosted its stake in Pfizer by 32.0% during the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after purchasing an additional 5,901,100 shares in the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.
A number of equities analysts have issued reports on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, March 6th. Berenberg Bank set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. UBS set a $42.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Leerink Swann increased their price target on Pfizer from $35.00 to $38.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. Finally, Jefferies Group set a $39.00 price target on Pfizer and gave the company a “hold” rating in a research note on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $39.40.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company’s revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $0.47 EPS. research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.70%. Pfizer’s dividend payout ratio (DPR) is currently 38.75%.
Pfizer announced that its Board of Directors has approved a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
In other news, insider Mikael Dolsten sold 69,699 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,037 shares of company stock valued at $9,064,785. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.